Breast Cancer

Overview

Curcumin has been more extensively studied in breast cancer than in almost any other cancer type. Research spans all major subtypes — triple-negative, HER2-positive, luminal (estrogen receptor-positive), and endocrine-resistant disease — and covers both laboratory investigations and early human trials.

The focus across this body of work is consistent: curcumin may help slow tumour growth, reduce resistance to conventional treatment, and support tolerability during therapy. It is being investigated as an adjunct alongside standard care, not as a replacement for it.

How Curcumin May Work in Breast Cancer

Curcumin appears to act on several pathways simultaneously. In plain terms, it may interfere with the signals that cancer cells use to grow, survive, spread, and resist treatment. Key mechanisms identified in laboratory studies include:

• Switching off NF-κB, a protein that cancer cells use to avoid destruction and drive inflammation

• Suppressing the PI3K/Akt/mTOR pathway — a central driver of tumour growth and therapy resistance

• Inhibiting MAPK/ERK signalling, which supports cancer cell proliferation

• Reducing VEGF, a protein that helps tumours grow new blood vessels (angiogenesis)

• Blocking epithelial-to-mesenchymal transition (EMT) — the process by which cancer cells become more mobile and invasive

• Triggering apoptosis (programmed cell death) via activation of caspase enzymes and downregulation of the survival protein Bcl-2

• Inducing G2/M cell cycle arrest, pausing cancer cell division

Findings by Breast Cancer Subtype

Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, leaving fewer targeted treatment options available. This makes multi-pathway agents like curcumin of particular interest.

Laboratory studies using TNBC cell lines (MDA-MB-231, SUM159) have shown that curcumin suppresses NF-κB–Snail signalling — a pathway that drives invasion — and downregulates key proteins involved in metastasis, including fibronectin, N-cadherin, and β-catenin. A 2024 study using RNA sequencing confirmed that curcumin significantly reduced mTOR, p-Akt, and N-cadherin expression in TNBC models, suggesting meaningful interference with the pathways most responsible for spread and aggressive behaviour.

HER2-Positive Breast Cancer

HER2-overexpressing breast cancers can be aggressive and treatment-resistant. In laboratory models using BT-474 and SK-BR-3 cell lines, curcumin has been shown to reduce HER-2 protein expression and block downstream signalling through Akt, MAPK, and NF-κB.

In a mouse model, curcumin alone reduced tumour volume by approximately 77%. When combined with trastuzumab (Herceptin), tumour regression approached 88% — a finding comparable to trastuzumab alone. While this is preclinical data, it raises the question of whether curcumin may support or complement HER2-targeted therapy, warranting further human investigation.

Luminal / Estrogen Receptor-Positive Breast Cancer

In ER-positive MCF-7 cell lines, curcumin has been shown to reduce cell proliferation and colony formation, downregulate estrogen receptor alpha (ERα), and suppress both proliferative and EMT-related proteins including PCNA, vimentin, and E-cadherin. These effects suggest curcumin may help slow the growth drivers of hormone-responsive breast cancer.

A 2024 study combined lab work in ER‑positive MCF‑7 cells with gene‑expression data from real breast cancer patients and found that curcumin reduces ERα and several ER‑driven proliferation and survival genes in the lab.
Those same genes (ESR1, CCND1, BCL2, EGFR, CTSD) are highly expressed in advanced luminal tumours, suggesting curcumin may be a plausible add‑on in ER‑positive, especially endocrine‑resistant, breast cancer.

Endocrine-Resistant Breast Cancer

Resistance to tamoxifen is one of the more difficult challenges in ER-positive disease. Laboratory research has shown that curcumin may restore tamoxifen sensitivity in resistant MCF-7 cell lines (LCC2 and LCC9) by simultaneously suppressing NF-κB, Src/FAK, Akt/mTOR, and an epigenetic modifier called EZH2. Combining curcumin with tamoxifen in these resistant models produced synergistic growth inhibition — a promising early finding for patients who have experienced treatment failure.

A 2025 study using nano-curcumin further demonstrated attenuation of tamoxifen resistance and reduced malignant progression in ER-positive breast cancer cells, again via inhibition of the PI3K/AKT/mTOR pathway.

Cancer Stem Cell Targeting

Cancer stem cells are a subpopulation of cells believed to drive recurrence and treatment resistance. They are identified by surface markers including CD44-positive/CD24-negative expression.

Laboratory studies have shown that curcumin reduces this stem cell marker profile, suppresses mammosphere formation, and inhibits the migratory capacity of breast cancer stem cells. Transcriptomic analysis (gene expression profiling) of curcumin-treated breast stem cells confirmed downregulation of several genes associated with stem cell identity, including ALDH1A3, CD49f, PROM1, and TP63. This area of research is still preclinical but is considered significant given the role of stem cells in relapse.

Aromatase Inhibition

Aromatase is an enzyme responsible for producing estrogen in postmenopausal women, and aromatase inhibitors (AIs) are a common treatment in hormone-sensitive breast cancer. A 2025 study found that cyclocurcumin — a natural analogue of curcumin — is a potent inhibitor of the aromatase enzyme, raising interest in its potential role in estrogen-dependent cancers. This is an early finding and requires further clinical investigation.

Chemosensitisation: Taxane Combinations

One of the more clinically relevant areas of breast cancer research is curcumin's potential to enhance the effect of chemotherapy drugs. Studies in breast cancer cell lines have demonstrated synergistic effects when curcumin is combined with taxanes (paclitaxel and docetaxel), including enhanced apoptosis and suppression of proliferative signalling.

A Phase I human trial combined curcumin (up to 6 g/day for 7 days per cycle) with standard-dose docetaxel in 14 patients with advanced or metastatic breast cancer. The combination was found to be well tolerated with no dose-limiting toxicity identified. This remains early-stage data but provides an important safety signal for future combination trials.

Radiotherapy Support

Several clinical trials have investigated whether curcumin can reduce the skin side effects of radiotherapy in breast cancer patients — a common and distressing complication called radiation dermatitis.

• A randomised, double-blind, placebo-controlled trial in 30 breast cancer patients found that oral curcumin (6 g/day, taken in divided doses during radiotherapy) significantly reduced the severity of radiation dermatitis. Fewer patients in the curcumin group developed moist desquamation — a severe form of skin breakdown — compared to placebo (28.6% versus 87.5%).

• A triple-blinded randomised controlled trial using nano-curcumin (80 mg/day) in 42 breast cancer patients similarly found reduced radiation-induced skin toxicity during treatment.

• A 2025 trial investigated a 2% topical curcumin gel applied during breast radiotherapy and reported reduced skin side effects compared to placebo.

These are small trials, but their consistency across different curcumin formulations and delivery methods is noteworthy.

Aromatase Inhibitor Joint Pain

Joint pain (arthralgia) is one of the most commonly reported side effects of aromatase inhibitors and frequently leads to treatment discontinuation. A 2024 randomised, placebo-controlled, double-blind clinical trial investigated curcumin supplementation in postmenopausal breast cancer patients taking aromatase inhibitors, examining its potential to reduce AI-associated joint pain and improve tolerability. Results from this trial add to the emerging picture of curcumin as a supportive agent during conventional treatment.

Tumour Microenvironment and Immune Modulation

The tumour microenvironment — the surrounding tissue, immune cells, and signalling molecules that influence cancer behaviour — is an active area of curcumin research. A 2025 review confirmed that curcumin modulates this environment through anti-inflammatory, antioxidant, and immunomodulatory effects, potentially enhancing the immune system's ability to recognise and respond to cancer cells. Curcumin has also been shown to activate AMPK (an energy-sensing enzyme) in TNBC cells, triggering autophagy while simultaneously suppressing AKT-driven proliferation and migration.

CDK4/6 inhibitor treatment — more curcumin context to consider

If you are looking at curcumin in ER-positive, HER2-negative disease and treatment includes abemaciclib or ribociclib, also see CDK4/6 Options and Supplement Considerations.

That page explains how curcumin and other common supplements may fit around CDK4/6 therapy.

It also covers liver monitoring, neutropenia, and the trade-offs between the two drugs.

Practical Interpretation for Patients

Curcumin is not a treatment for breast cancer, and no clinical trial has established it as a standalone therapy. What the research suggests — across a substantial and growing body of laboratory and early human studies — is that curcumin may offer meaningful support as an adjunct:

• It may help sensitise cancer cells to chemotherapy and radiotherapy

• It may help reduce some treatment side effects, including skin reactions from radiation

• It may help address pathways associated with drug resistance

• It appears to target cancer stem cells, which are implicated in recurrence

• It has been well tolerated in the human trials conducted to date

Standard oncology treatment should always be the first priority. Curcumin is best understood as a potential complement to conventional care, used in discussion with your treating team.

References for Curcumin in Breast Cancer

MCS Formulas Curcumin C3 Pro Liposomal:
https://www.mcsformulas.com/vitamins-supplements/curcumin-c3-liposomal/ref/14

If using MCS Formulas, the discount code abbey5 gives 5% off and supports patients' worldwide access to more free Healing Cancer Study Support resources.

Curcumin sensitizes human breast cancer cells to chemotherapy-induced apoptosis
https://pubmed.ncbi.nlm.nih.gov/24318305/

Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
https://pubmed.ncbi.nlm.nih.gov/19901561/

Curcumin: Modulator of Key Molecular Signalling Pathways in Hormone-Independent Breast Cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC8307022/

Curcumin suppresses metastasis of triple-negative breast cancer via Wnt/β-catenin and PI3K/Akt/mTOR pathways (2024)
https://pubmed.ncbi.nlm.nih.gov/38394486/

The Potential Utility of Curcumin in the Treatment of HER-2 Overexpressed Breast Cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC3162976/

Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells
https://pmc.ncbi.nlm.nih.gov/articles/PMC6090267/

Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in Endocrine-Resistant Breast Cancer Cells
https://pmc.ncbi.nlm.nih.gov/articles/PMC6269686/

Effects of Curcumin and Estrogen Receptor Alpha in Luminal Breast Cancer (2024)
https://pmc.ncbi.nlm.nih.gov/articles/PMC11353822/

Curcumin targets breast cancer stem-like cells with microtentacles
https://pmc.ncbi.nlm.nih.gov/articles/PMC3990412/

Transcriptomic profiling of curcumin-treated human breast stem cells identifies targets for breast cancer prevention and treatment
https://pubmed.ncbi.nlm.nih.gov/27306423/

Research progress on the impact of curcumin on immune responses in breast cancer (2025)
https://pmc.ncbi.nlm.nih.gov/articles/PMC12451429/

Cyclocurcumin potently inhibits human aromatase as a potential breast cancer therapeutic (2025)
https://pubmed.ncbi.nlm.nih.gov/39746524/

Curcumin for Radiation Dermatitis: A Randomised, Double-Blind, Placebo-Controlled Trial in Breast Cancer Patients
https://pmc.ncbi.nlm.nih.gov/articles/PMC3998827/

Effect of Nano-Curcumin on Radiotherapy-Induced Skin Reactions in Breast Cancer (Randomised Controlled Trial)
https://pubmed.ncbi.nlm.nih.gov/35747962/

Topical Curcumin Gel for Prevention of Radiation-Induced Dermatitis in Breast Cancer (2025)
https://pubmed.ncbi.nlm.nih.gov/40145664/

Randomised placebo-controlled double-blind clinical trial of curcumin in breast cancer patients on aromatase inhibitor therapy (2024)
https://pubmed.ncbi.nlm.nih.gov/38280052/

Nano-curcumin attenuates tamoxifen resistance and malignant progression in ER-positive breast cancer (2025)
https://pubmed.ncbi.nlm.nih.gov/40617262/